Merck’s TROP2 antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) secured its first global Phase 3 success ahead of schedule in advanced endometrial cancer, meeting both overall survival and progression-free survival endpoints. The result extends Merck’s push to broaden sacituzumab’s role across women’s cancers. The win matters commercially because ADCs have struggled historically in endometrial indications where agents targeting FRα and HER2 have not yet delivered consistent survival improvements. Merck framed the trial outcome as opening a wider path for global adoption while it continues to scale its ADC development strategy.